Researchers at Nuffield Laboratory of Ophthalmology, University of Oxford and the Oxford Eye Hospital, NHS Foundation Trust, has reported that a surrogate biomarker (comprising the… Read More »Clinical trial endpoints use EZ and ELM biomarkers for selecting patients for treatments on X-linker retinitis pigmentosa.
Researchers at the Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy and the Department of Ophthalmology, University of Oslo, Norway, have published a… Read More »A systematic review of retinitis pigmentosa and its therapeutic approaches report different treatments and disorders.
An international consortium of researchers on a multi-centre study on congenital stationary night blindness (CSNB), led by Oregon Health and Science University Casey Eye Institute,… Read More »An international multi-centre study on congenital stationary night blindness (CSNB) report several genetic variants on myopia.
Researchers at Janssen Pharmaceuticals N.V. and the ERN-EYE Network at the Center for Retinitis Pigmentosa of Veneto Region, Camposampiero Hospital, Padua, Italy, have reported results… Read More »Results from a cross sectional study of XLRP patients suggest that several healthcare systems require early diagnosis and effective management of patients.
Researchers at UCL Institute of Ophthalmology, University College London, and Moorfields Eye Hospital, have reported a detailed natural history, retinal imaging dataset and clinical features… Read More »A first in-depth retrospective longitudinal study of Usher syndrome on USH1D, providing key natural history, image data and clinical features.
Researchers at the Center for Ophthalmic Bioinformatics Research at the Cole Eye Institute, Cleveland, Ohio, have reported that the prevalence of diabetic retinopathy (DR) changed… Read More »Early warning signs of diabetic retinopathy (DR) in clinics shows exponentially increases in prevalence on type 1 DR and type 2 DR.
Researchers for the Foundation Fighting Blindness (FFB) Clinical Consortium Investigator Group, based in Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan,… Read More »USH2A: self-reported functional vision measured in associated retinal degeneration by the Michigan Retinal Degeneration Questionnaire (MRDQ).
A new real-world study, led by Massachusetts General Hospital, Harvard Medical School, Boston, US, have reported a major adverse event on hydroxychloroquine retinopathy, with an… Read More »Hydroxychloroquine dose and duration of use are associated with the risk of hydroxychloroquine retinopathy in a US study.
A large real-world prospective study on the long-term effectiveness and safety of faricimab and “Port Delivery System with ranibizumab” (PDS), for nAMD or DME, is… Read More »Real-world data on treatment of AMD/DME patients with faricimab and port delivery system with ranibizumab will run to 2027 (“VOYAGER” ).
Clinical researchers based in Oregon Health and Science University (OHSU), Portland and the Ocular Genomics Institute, Mass Eye and Ear, Harvard University, have published the… Read More »CRISPR experimental treatment on a Phase 1/2 study for LCA10 patients report meaningful improvements.
